Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kymera Therapeutics, Inc.KYMR · Entity 3545 | Director · Chief Executive Officer | October 01, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kymera Therapeutics, Inc.
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 666,568 |
Ending reported balance
After 2026-10-01 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 30,000 · Balance 696,568 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. Row 2 · 2026-10-01 · Sale · Disposed 3,525 · Balance 693,043 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.93 to $111.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-10-01 · Sale · Disposed 5,506 · Balance 687,537 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.97 to $112.92 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-10-01 · Sale · Disposed 4,876 · Balance 682,661 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.95 to $113.88 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 5 · 2026-10-01 · Sale · Disposed 7,601 · Balance 675,060 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.94 to $114.91 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 6 · 2026-10-01 · Sale · Disposed 8,230 · Balance 666,830 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.94 to $115.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 7 · 2026-10-01 · Sale · Disposed 262 · Balance 666,568 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.16 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.08 · Expires 2029-11-13 | Direct | 60,000 |
Reported balance
After 2026-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-01 · Exercise / conversion · Disposed 30,000 · Balance 60,000 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F8: The shares underlying this stock option are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.93 to $111.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.97 to $112.92 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.95 to $113.88 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.94 to $114.91 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.94 to $115.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.16 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8: The shares underlying this stock option are fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 16, 2021 Filed Dec 16, 2021 21:49 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 8,000 | $2.08 | $16,640.00 |
DisclosureSEC source: 0000899243-21-048614 · doc4.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 11, 2021 Filed Oct 12, 2021 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,456 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-039857 · doc4.xml · derivative · entry 12 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,725 Underlying: Common Stock · 6,456 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones. Read SEC document |
| October 11, 2021 Filed Oct 12, 2021 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 744 | $54.50 | $40,546.44 |
DisclosureSEC source: 0000899243-21-039857 · doc4.xml · nonDerivative · entry 10 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464,199 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.28 to $54.60. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 11, 2021 Filed Oct 12, 2021 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 5,712 | $53.58 | $306,043.82 |
DisclosureSEC source: 0000899243-21-039857 · doc4.xml · nonDerivative · entry 9 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464,943 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.19 to $54.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 11, 2021 Filed Oct 12, 2021 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 6,456 | $2.08 | $13,428.48 |
DisclosureSEC source: 0000899243-21-039857 · doc4.xml · nonDerivative · entry 8 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 41,544 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-039857 · doc4.xml · derivative · entry 11 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,181 Underlying: Common Stock · 41,544 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 271 | $61.87 | $16,766.77 |
DisclosureSEC source: 0000899243-21-039857 · doc4.xml · nonDerivative · entry 7 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464,199 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 670 | $60.32 | $40,412.06 |
DisclosureSEC source: 0000899243-21-039857 · doc4.xml · nonDerivative · entry 6 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464,470 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.91 to $60.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 7,920 | $59.28 | $469,462.75 |
DisclosureSEC source: 0000899243-21-039857 · doc4.xml · nonDerivative · entry 5 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 465,140 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.90 to $59.81. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,078 | $57.29 | $119,045.92 |
DisclosureSEC source: 0000899243-21-039857 · doc4.xml · nonDerivative · entry 4 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 473,060 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.20 to $58.14. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 9,369 | $56.82 | $532,390.61 |
DisclosureSEC source: 0000899243-21-039857 · doc4.xml · nonDerivative · entry 3 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,138 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.19 to $57.185. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 21,236 | $55.56 | $1,179,867.91 |
DisclosureSEC source: 0000899243-21-039857 · doc4.xml · nonDerivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 484,507 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.10 to $56.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 41,544 | $2.08 | $86,411.52 |
DisclosureSEC source: 0000899243-21-039857 · doc4.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 505,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2021 Filed Aug 19, 2021 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-033636 · doc4.xml · derivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,424 Underlying: Common Stock · 12,000 shares Expires 2029-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| August 19, 2021 Filed Aug 19, 2021 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 12,000 | $2.08 | $24,960.00 |
DisclosureSEC source: 0000899243-21-033636 · doc4.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 20:14 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,037 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001209191-21-049922 · doc4.xml · derivative · entry 6 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,725 Underlying: Common Stock · 1,037 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 20:14 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,037 | $60.03 | $62,252.87 |
DisclosureSEC source: 0001209191-21-049922 · doc4.xml · nonDerivative · entry 4 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,199 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 20:14 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 1,037 | $2.08 | $2,156.96 |
DisclosureSEC source: 0001209191-21-049922 · doc4.xml · nonDerivative · entry 3 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 453,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 20:14 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,669 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001209191-21-049922 · doc4.xml · derivative · entry 5 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,762 Underlying: Common Stock · 5,669 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 20:14 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 5,669 | $60.07 | $340,533.43 |
DisclosureSEC source: 0001209191-21-049922 · doc4.xml · nonDerivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,199 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.78. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 20:14 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 5,669 | $2.08 | $11,791.52 |
DisclosureSEC source: 0001209191-21-049922 · doc4.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 457,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2021 Filed Aug 2, 2021 21:53 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,456 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001209191-21-049110 · doc4.xml · derivative · entry 11 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,431 Underlying: Common Stock · 23,456 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones. Read SEC document |
| August 02, 2021 Filed Aug 2, 2021 21:53 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 300 | $62.21 | $18,662.46 |
DisclosureSEC source: 0001209191-21-049110 · doc4.xml · nonDerivative · entry 8 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,199 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.205 to $62.21. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 02, 2021 Filed Aug 2, 2021 21:53 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,524 | $61.28 | $93,386.61 |
DisclosureSEC source: 0001209191-21-049110 · doc4.xml · nonDerivative · entry 7 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,499 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.00 to $61.98. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 02, 2021 Filed Aug 2, 2021 21:53 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 21,632 | $60.21 | $1,302,354.56 |
DisclosureSEC source: 0001209191-21-049110 · doc4.xml · nonDerivative · entry 6 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,023 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.86. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 02, 2021 Filed Aug 2, 2021 21:53 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 23,456 | $2.08 | $48,788.48 |
DisclosureSEC source: 0001209191-21-049110 · doc4.xml · nonDerivative · entry 5 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2021 Filed Aug 2, 2021 21:53 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,279 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001209191-21-049110 · doc4.xml · derivative · entry 10 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,887 Underlying: Common Stock · 6,279 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones. Read SEC document |
| July 30, 2021 Filed Aug 2, 2021 21:53 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 6,279 | $60.07 | $377,166.97 |
DisclosureSEC source: 0001209191-21-049110 · doc4.xml · nonDerivative · entry 4 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,199 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 30, 2021 Filed Aug 2, 2021 21:53 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 6,279 | $2.08 | $13,060.32 |
DisclosureSEC source: 0001209191-21-049110 · doc4.xml · nonDerivative · entry 3 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 458,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 29, 2021 Filed Aug 2, 2021 21:53 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 680 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001209191-21-049110 · doc4.xml · derivative · entry 9 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,166 Underlying: Common Stock · 680 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones. Read SEC document |
| July 29, 2021 Filed Aug 2, 2021 21:53 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 680 | $60.00 | $40,800.00 |
DisclosureSEC source: 0001209191-21-049110 · doc4.xml · nonDerivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,199 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. Read SEC document |
| July 29, 2021 Filed Aug 2, 2021 21:53 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 680 | $2.08 | $1,414.40 |
DisclosureSEC source: 0001209191-21-049110 · doc4.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 28, 2021 Filed Jul 28, 2021 20:57 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,864 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001209191-21-048437 · doc4.xml · derivative · entry 6 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,846 Underlying: Common Stock · 3,864 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones. Read SEC document |
| July 28, 2021 Filed Jul 28, 2021 20:57 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 3,864 | $60.15 | $232,409.55 |
DisclosureSEC source: 0001209191-21-048437 · doc4.xml · nonDerivative · entry 4 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,199 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 28, 2021 Filed Jul 28, 2021 20:57 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 3,864 | $2.08 | $8,037.12 |
DisclosureSEC source: 0001209191-21-048437 · doc4.xml · nonDerivative · entry 3 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 20:57 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,015 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001209191-21-048437 · doc4.xml · derivative · entry 5 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,710 Underlying: Common Stock · 9,015 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones. Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 20:57 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 9,015 | $60.15 | $542,236.92 |
DisclosureSEC source: 0001209191-21-048437 · doc4.xml · nonDerivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,199 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 20:57 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 9,015 | $2.08 | $18,751.20 |
DisclosureSEC source: 0001209191-21-048437 · doc4.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 461,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 48,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001209191-21-046174 · doc4.xml · derivative · entry 6 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,725 Underlying: Common Stock · 48,000 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 595 | $51.64 | $30,723.90 |
DisclosureSEC source: 0001209191-21-046174 · doc4.xml · nonDerivative · entry 5 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,199 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.60 to $51.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 6,372 | $50.96 | $324,717.12 |
DisclosureSEC source: 0001209191-21-046174 · doc4.xml · nonDerivative · entry 4 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,794 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.45 to $51.44. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 23,803 | $49.71 | $1,183,332.82 |
DisclosureSEC source: 0001209191-21-046174 · doc4.xml · nonDerivative · entry 3 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459,166 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.44 to $50.42. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 17,230 | $49.15 | $846,854.50 |
DisclosureSEC source: 0001209191-21-046174 · doc4.xml · nonDerivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 482,969 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.44 to $49.42. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 48,000 | $2.08 | $99,840.00 |
DisclosureSEC source: 0001209191-21-046174 · doc4.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2021 Filed Jun 14, 2021 21:57 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-023664 · doc4.xml · derivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,424 Underlying: Common Stock · 40,000 shares Expires 2029-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| June 14, 2021 Filed Jun 14, 2021 21:57 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 40,000 | $2.08 | $83,200.00 |
DisclosureSEC source: 0000899243-21-023664 · doc4.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 20:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,009 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-023228 · doc4.xml · derivative · entry 5 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,725 Underlying: Common Stock · 23,009 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 20:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 5,994 | $52.53 | $314,845.04 |
DisclosureSEC source: 0000899243-21-023228 · doc4.xml · nonDerivative · entry 4 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,199 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.02 to $52.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 20:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 6,912 | $51.46 | $355,724.01 |
DisclosureSEC source: 0000899243-21-023228 · doc4.xml · nonDerivative · entry 3 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 418,193 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.00 to $51.99. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 20:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 10,103 | $50.63 | $511,537.12 |
DisclosureSEC source: 0000899243-21-023228 · doc4.xml · nonDerivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,105 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.96. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.